摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2,5-dichlorophenyl)-2-aminoethanol | 59085-40-4

中文名称
——
中文别名
——
英文名称
N-(2,5-dichlorophenyl)-2-aminoethanol
英文别名
2-(2,5-dichloro-anilino)-ethanol;2-(2,5-Dichlor-anilino)-aethanol;2-(2,5-Dichloroanilino) ethanol;2-(2,5-dichloroanilino)ethanol
N-(2,5-dichlorophenyl)-2-aminoethanol化学式
CAS
59085-40-4
化学式
C8H9Cl2NO
mdl
——
分子量
206.072
InChiKey
MSIUAAZLLHHLHU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    53-54 °C(Solv: ethanol (64-17-5))
  • 沸点:
    163-165 °C(Press: 3 Torr)
  • 密度:
    1.403±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    32.3
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis, Screening, and Molecular Modeling of New Potent and Selective Antagonists at the α1d Adrenergic Receptor
    摘要:
    In the present study, more than 75 compounds structurally related to BMY 7378 have been designed and synthesized. Structural variations of each part of the reference molecule have been introduced, obtaining highly selective ligands for the aid adrenergic receptor. The molecular determinants for selectivity at this receptor are essentially, held by the phenyl substituent in the phenylpiperazine moiety. The integration of an extensive SAR analysis with docking simulations using the rhodopsin-based models of the three alpha(1)-AR subtypes and of the 5-HT1A receptor provides significant insights into the characterization of the receptor binding sites as well as into the molecular determinants of ligand selectivity at the alpha(1d)-AR and the 5-HT1A receptors. The results of multiple copies simultaneous search (MCSS) on the substituted phenylpiperazines together with those of manual docking of compounds BAN 7378 and 69 into the putative binding sites of the alpha(1a)-AR, alpha(1b)-AR, alpha(1d)-AR, and the 5-HT1A receptors suggest that the phenylpiperazine moiety would dock into a site formed by amino acids in helices 3, 4, 5, 6 and extracellular loop 2, (E2), whereas the spirocyclic ring of the ligand docks into a site formed by amino acids of helices 1, 2, 3, and 7. This docking mode is consistent with the SAR data produced in this work. Furthermore, the binding site of the imide moiety does not allow for the simultaneous involvement of the two carbonyl oxygen atoms in H-bonding, interactions, consistent with the SAR data, in particular with the results obtained with the lactam derivative 128. The results of docking simulations also suggest that the second and third extracellular loops may act as selectivity filters for the substituted phenylpiperazines. The most potent and selective compounds for alpha(1d) adrenergic receptor, i.e., 69 (Rec 26D/038) and 128 (Rec 26D/073), are characterized by the presence of the 2,5-dichlorophenylpiperazine moiety.
    DOI:
    10.1021/jm030944+
  • 作为产物:
    参考文献:
    名称:
    Petrow; Lagutschewa, Zhurnal Obshchei Khimii, 1953, vol. 23, p. 403; engl. Ausg. S. 411
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Chemoselective<i>O</i>-formyl and<i>O</i>-acyl protection of alkanolamines, phenoxyethanols and alcohols catalyzed by nickel(<scp>ii</scp>) and copper(<scp>ii</scp>)-catalysts
    作者:Rahul B. Sonawane、Swapnali R. Sonawane、Nishant K. Rasal、Sangeeta V. Jagtap
    DOI:10.1039/d0gc00520g
    日期:——
    alkanolamines, that have both amines and alcohols as reactive functional groups. Achieving 100% selectivity for O-formyl and O-acyl protection of alkanolamines is one of the examples of such reactions. To avoid protection and deprotection steps and overcome this problem, a novel chemoselective, efficient, and simple protocol for functional group protection as O-formylation and O-acylation of alkanolamines and
    对于具有胺和醇作为反应性官能团的双官能化合物(例如烷醇胺),实现化学选择性始终是至关重要且具有挑战性的。这种反应的例子之一是使烷醇胺的O-甲酰基和O-酰基保护的选择性达到100%。为避免保护和脱保护步骤并克服这一问题,Ni(Ni(Ni))催化了一种新的化学选择性,有效且简单的官能团保护方案,如烷醇胺和苯氧基乙醇的O-甲酰化和O-酰化以及醇和胺之间的竞争性O-选择性。II)和Cu(II)在均相介质中仅以5 mol%的催化剂负载量与8-羟基喹啉形成络合物。在不存在用于室温下以甲酸为甲酰基源的O-甲酰化溶剂和在70°C下以乙酸为酰基源的O-酰化条件下,可获得良好或优异的收率。另外,在该反应过程中产生最少的废水和废物,因为相应的酸的钠盐可以在该过程中回收并可以重复使用。这种化学反应容易耐受各种官能团,如20个对烷醇胺的O-甲酰化和O-酰化具有100%化学选择性的实例以及30个O-甲酰化和在已成功合
  • [EN] CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR<br/>[FR] AMIDES ET IMIDES CYCLIQUES POSSEDANT UNE ACTIVITE ANTAGONISTE SELECTIVE AU NIVEAU DU RECEPTEUR ADRENERGIQUE 1D
    申请人:RECORDATI CHEM PHARM
    公开号:WO2001005765A1
    公开(公告)日:2001-01-25
    Compounds (I) R and R1 independently = H or C1-C4 alkyl or together = (CH2)2-6, n=0 or 1, ...... is a single or a double bond, A=CO or CH2, A1 represents a CO or CH2 or CH, each R3 independently = H or C1-C4 alkyl, B is B1 or B2 (B2); Y=N or CH, R2 = halogen, C1-C4 alkyl or CN, R5 = halogen, C1-C4 alkyl, polyfluoroalkyl or NO2, R6 = H or halogen, m is 1 to 3, Z = O, S, NH or NMe) interact selectively with the α1D subtype of the α1 adrenergic receptor. This selectively makes these compounds useful agents in tissues particularly rich in α1D adrenergic receptors, thus useful in reducing contractility of an unstable urinary bladder, in the treatment and prevention of atherosclerosis as they are inhibitors of noradrenaline-mediated cell proliferation in smooth muscles, and in reducing vascular adrenergic tone. The preparation of these compounds, their enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them are also claimed.
    化合物(I)中,R和R1分别为H或C1-C4烷基,或者在一起为(CH2)2-6,n=0或1,......为单键或双键,A=CO或CH2,A1代表CO或CH2或CH,每个R3独立地为H或C1-C4烷基,B为B1或B2(B2);Y=N或CH,R2=卤素,C1-C4烷基或CN,R5=卤素,C1-C4烷基,多氟烷基或NO2,R6=H或卤素,m为1到3,Z=O,S,NH或NMe)与α1D亚型的α1肾上腺素受体选择性相互作用。这种选择性使得这些化合物在α1D肾上腺素受体特别丰富的组织中成为有用的药物,因此可用于减少不稳定的膀胱的收缩性,在动脉粥样硬化的治疗和预防中,因为它们是平滑肌中去甲肾上腺素介导的细胞增殖的抑制剂,以及减少血管肾上腺素张力。还声明了这些化合物、它们的对映体、对映异构体、N-氧化物和药学上可接受的盐的制备以及含有它们的制药组合物。
  • CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR
    申请人:RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
    公开号:EP1200406B1
    公开(公告)日:2004-11-24
  • Schostakowskii; Tschekulaewa, Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya, 1957, p. 75,76; engl. Ausg. S. 79, 80
    作者:Schostakowskii、Tschekulaewa
    DOI:——
    日期:——
  • Dustmukhamedov,T.T. et al., Journal of general chemistry of the USSR, 1976, vol. 46, p. 297 - 300
    作者:Dustmukhamedov,T.T. et al.
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐